KR102918269B1 - 펩타이드 활성화 제제 - Google Patents

펩타이드 활성화 제제

Info

Publication number
KR102918269B1
KR102918269B1 KR1020207036029A KR20207036029A KR102918269B1 KR 102918269 B1 KR102918269 B1 KR 102918269B1 KR 1020207036029 A KR1020207036029 A KR 1020207036029A KR 20207036029 A KR20207036029 A KR 20207036029A KR 102918269 B1 KR102918269 B1 KR 102918269B1
Authority
KR
South Korea
Prior art keywords
cells
cell
lck
peptide
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207036029A
Other languages
English (en)
Korean (ko)
Other versions
KR20210021984A (ko
Inventor
마이클 발렌타인 아그레즈
Original Assignee
인터크 펩타이드 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901673A external-priority patent/AU2018901673A0/en
Application filed by 인터크 펩타이드 테라퓨틱스 리미티드 filed Critical 인터크 펩타이드 테라퓨틱스 리미티드
Publication of KR20210021984A publication Critical patent/KR20210021984A/ko
Application granted granted Critical
Publication of KR102918269B1 publication Critical patent/KR102918269B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207036029A 2018-05-15 2019-05-15 펩타이드 활성화 제제 Active KR102918269B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (2)

Publication Number Publication Date
KR20210021984A KR20210021984A (ko) 2021-03-02
KR102918269B1 true KR102918269B1 (ko) 2026-01-28

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036029A Active KR102918269B1 (ko) 2018-05-15 2019-05-15 펩타이드 활성화 제제

Country Status (8)

Country Link
US (2) US11912789B2 (enExample)
EP (1) EP3794014A4 (enExample)
JP (1) JP7386852B2 (enExample)
KR (1) KR102918269B1 (enExample)
CN (1) CN112399970B (enExample)
AU (1) AU2019268412B2 (enExample)
CA (1) CA3100074A1 (enExample)
WO (1) WO2019218016A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
KR20240044517A (ko) * 2021-08-20 2024-04-04 인터크 펩타이드 테라퓨틱스 리미티드 암 및 암 요법과 연관된 자가면역을 포함한 자가면역을 치료하기 위한 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138236A1 (en) 2008-05-14 2009-11-19 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii petptides derived from survivin
WO2010094085A1 (en) 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
CA2539914A1 (en) * 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20050187147A1 (en) * 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
CA2697896C (en) 2007-09-18 2016-06-28 Green Peptide Co., Ltd. Ctl inducer composition
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
NZ713461A (en) * 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2720705A4 (en) * 2011-06-16 2015-02-18 Jolla Inst Allergy Immunolog COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING PKC-THETA PATHOLOGIES, UNWANTED IMMUNE REACTIONS AND DISEASES
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138236A1 (en) 2008-05-14 2009-11-19 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii petptides derived from survivin
WO2010094085A1 (en) 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
WO2013110120A1 (en) 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kowalczyk R. et al, Peptides and Peptidebased Biomaterials and their Biomedical Applications 1030:pp.185~227 (2017.)*

Also Published As

Publication number Publication date
US20250019397A1 (en) 2025-01-16
JP2021523946A (ja) 2021-09-09
US20210214391A1 (en) 2021-07-15
CA3100074A1 (en) 2019-11-21
WO2019218016A1 (en) 2019-11-21
CN112399970A (zh) 2021-02-23
EP3794014A1 (en) 2021-03-24
JP7386852B2 (ja) 2023-11-27
US11912789B2 (en) 2024-02-27
KR20210021984A (ko) 2021-03-02
AU2019268412B2 (en) 2024-11-07
CN112399970B (zh) 2025-12-12
EP3794014A4 (en) 2022-03-16
AU2019268412A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
US20260103488A1 (en) Activating agents
US20250019397A1 (en) Peptide Activating Agent
Geng et al. TLR5 ligand–secreting T cells reshape the tumor microenvironment and enhance antitumor activity
KR20190126798A (ko) 당뇨병 치료를 위한 펩티드 및 방법
KR20230131481A (ko) Hiv 백신 및 이의 사용 방법
Middelburg et al. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent
JP2025163127A (ja) 同種異系腫瘍細胞ワクチン
JP2020532300A (ja) がんの処置のためのｂｃｍａおよびｔａｃｉ抗原に特異的な免疫原性ペプチド
CA3137031A1 (en) Compositions and methods for treating t cell exhaustion
KR102530161B1 (ko) 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도
US11702632B2 (en) Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease
CN108144049A (zh) 泛素化途径相关因子在调控调节性t细胞功能中的应用
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
WO2022234063A1 (en) Method for constitutive malt1 protease activation
JP7212942B2 (ja) Ｆｏｘｐ３結合ペプチド及びその使用
CA3184316C (fr) Complexe immunomodulateur et ses applications pour la therapie
TWI921717B (zh) Hiv疫苗及使用方法
Mohan The role of LKB1 spliceoforms in iTreg-Th17 plasticity and their interactions with PKCθ and SIRT1 downstream of IL-6 signaling
WO2025247951A1 (en) Fyn kinase inhibitors, combinations and uses thereof
Yan et al. SIRPA suppresses integrin-dependent virus endocytosis
Kujawa Development of small molecule immunomodulators of the human immune system for cancer therapy
Schoufour No el insights into MHC-I function using CRISPR/Cas9 screens

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)